Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT04017650 |
TitleEncorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | Phase
Phase 1, Phase 2
|
Date Added 2019-07-12 |
Location
Texas, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
cetuximab, encorafenib, Nivolumab |
Tags
MSS/ MMRp
|
| NCT ID NCT03711058 |
TitleStudy of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer | Phase
Phase 1, Phase 2
|
Date Added 2018-10-18 |
Location
Maryland, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Completed
|
Drugs
Copanlisib, Nivolumab |
Tags
MSS/ MMRp
|
| NCT ID NCT05167409 |
TitleA Study of ALX148 With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2021-12-22 |
Location
Arizona, United States
Colorado, United States New Jersey, United States Virginia, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
ALX148, cetuximab, Evorpacept (ALX148), Pembrolizumab, Erbitux, Keytruda |
Tags
MSS/ MMRp
|
| NCT ID NCT03727763 |
TitleCetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT) | Phase
Phase 2
|
Date Added 2018-11-01 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
cetuximab, Vemurafenib |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04708470 |
TitlePhase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer | Phase
Phase 1, Phase 2
|
Date Added 2021-01-14 |
Location
Maryland, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Bintrafusp alfa, Entinostat, NHS-IL12 |
Tags
MSS/ MMRp
|
| NCT ID NCT04362839 |
TitleRegorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer | Phase
Phase 1
|
Date Added 2020-04-27 |
Location
California, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Ipilimumab, Nivolumab, Regorafenib, Opdivo, Stivarga, Yervoy |
Tags
MSS/ MMRp
|
| NCT ID NCT03796884 |
TitleLinaclotide in Treating Patients With Stages 0-3 Colorectal Cancer | Phase
Phase 2
|
Date Added 2019-01-08 |
Location
Pennsylvania, United States
Washington, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Linaclotide |
Tags
MSS/ MMRp
|
| NCT ID NCT02864485 |
TitleLiving Donor Liver Transplantation for Unresectable Colorectal Cancer Liver Metastases | Phase
Not Applicable
|
Date Added 2016-08-12 |
Location
Canada
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04050709 |
TitleQUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers | Phase
Phase 1
|
Date Added 2019-08-08 |
Location
California, United States
|
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
PD-L1 t-haNK |
Tags
MSS/ MMRp
|
| NCT ID NCT02675946 |
TitleCGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | Phase
Phase 1
|
Date Added 2016-02-05 |
Location
California, United States
Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Hawaii, United States Illinois, United States Indiana, United States Maryland, United States Massachusetts, United States Nebraska, United States New Jersey, United States North Carolina, United States Pennsylvania, United States South Dakota, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States Taiwan |
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
cetuximab, CGX1321, encorafenib, Pembrolizumab, Keytruda |
Tags
MSS/ MMRp
|




